SCHEMBL3563867

SCHEMBL3563867

Cc1ccc(S(=O)(=O)n2c(C)c(OCCN(C)C)c3cc(Br)cc(Br)c32)c(Br)c1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C19 P33261 1/20 0.38
KDM4E B2RXH2 9/20 0.35
ALDH1A1 P00352 7/20 0.34
TDP1 Q9NUW8 3/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
UTS2R Q9UKP6 1/20 0.33
LMNA P02545 2/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
MAPK1 P28482 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HTR7 P34969 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3564013 0.91 HTR6 (0.39) UTS2RHTR7
SCHEMBL3562850 0.90 CYP1A2 (0.37) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL3559197 0.89 HTR7 (0.39) CYP1A2CYP2D6KDM4EALDH1A1MEN1
SCHEMBL3559200 0.88 HTR6 (0.38) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL3935893 0.87 ACLY (0.35) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL3557164 0.86 CYP1A2 (0.38) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL3567118 0.85 KDM4E (0.38) CYP1A2CYP2D6CYP2C19KDM4EALDH1A1
SCHEMBL3553702 0.85 HTR6 (0.39) ALDH1A1UTS2RMAPK1
SCHEMBL3562569 0.85 HTR6 (0.37) CYP1A2CYP2D6KDM4EALDH1A1MEN1
SCHEMBL3556559 0.84 HTR6 (0.45) CYP1A2CYP2D6KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP claimed
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 US disclosed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 US disclosed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT CYP1A2 52/4885CYP2D6 24/4885CYP2C19 37/4885
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT CYP1A2 52/4885CYP2D6 24/4885CYP2C19 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.